Document is current
Any future updates will be listed below
-
Authors
Voogd, Daphne W. M.
Lucassen, Merel J. J. https://orcid.org/0000-0003-4007-9449
van der Noll, Ruud
Zielhuis, Sybrand W. J.
Boss, David
Beijnen, Jos H.
Rosing, Hilde
Tibben, Matthijs
Huitema, Alwin D. R.
Schellens, Jan H. M.
Steeghs, Neeltje
-
Funding
Funding for this research was provided by:
Pharmaceuticals Bayer
- License Information
-
More Information
Article History
Received: 5 February 2025
Accepted: 8 April 2025
First Online: 14 May 2025
Declarations
:
: The following authors declare no conflict of interest: Daphne W.M. Voogd, Merel J.J. Lucassen, Ruud van der Noll, Sybrand Zielhuis, David Boss, Jos H. Beijnen, Hilde Rosing, Matthijs Tibben, and Alwin D.R. Huitema. Neeltje Steeghs provided consultation or attended advisory boards for Boehringer Ingelheim, Bristol-Myers Squibb, Ellipses Pharma, GlaxoSmithKline, and Incyte; received research grants from Abbvie, Actuate Therapeutics, Amgen, Anaveon, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, CellCentric, Cogent Biosciences, Cresecendo Biologics, Deciphera, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, Janssen, Kling Biotherapeutics, Lixte, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Pfizer, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, and Zentalis. Jan H.M. Schellens is share and patent holder of oral taxanes and CMO of Modra Pharmaceuticals and Lixte Biotechnology. All payments were to the Netherlands Cancer Institute and outside the submitted work.
: The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice, local institutional review board ethical approval, and applicable regulatory requirements. All patients provided written informed consent.
